Aroa Biosurgery Limited Stock

Equities

ARX

NZARXE0001S1

Medical Equipment, Supplies & Distribution

Market Closed - Australian S.E. 02:10:46 2024-05-10 EDT 5-day change 1st Jan Change
0.515 AUD +0.98% Intraday chart for Aroa Biosurgery Limited +3.00% -37.95%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 67.78M 40.78M 61.69M 55.79M Sales 2025 * 87.08M 52.39M 79.26M 71.68M Capitalization 193M 116M 175M 159M
Net income 2024 * -6M -3.61M -5.46M -4.94M Net income 2025 * 2M 1.2M 1.82M 1.65M EV / Sales 2024 * 2.45 x
Net cash position 2024 * 26.56M 15.98M 24.18M 21.87M Net cash position 2025 * 28.87M 17.37M 26.27M 23.76M EV / Sales 2025 * 1.88 x
P/E ratio 2024 *
-26.1 x
P/E ratio 2025 *
83.3 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 73.03%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.98%
1 week+3.00%
Current month+3.00%
1 month-10.43%
3 months-12.71%
6 months-35.22%
Current year-37.95%
More quotes
1 week
0.50
Extreme 0.5
0.55
1 month
0.48
Extreme 0.475
0.58
Current year
0.48
Extreme 0.475
0.87
1 year
0.48
Extreme 0.475
1.02
3 years
0.48
Extreme 0.475
1.30
5 years
0.48
Extreme 0.475
1.75
10 years
0.48
Extreme 0.475
1.75
More quotes
Date Price Change Volume
24-05-10 0.515 +0.98% 99 706
24-05-09 0.51 -1.92% 617,042
24-05-08 0.52 -1.89% 498,622
24-05-07 0.53 -1.85% 55,576
24-05-06 0.54 -0.92% 388,837

Delayed Quote Australian S.E., May 10, 2024 at 02:10 am

More quotes
Aroa Biosurgery Limited is a soft-tissue regeneration company. It develops, manufactures, sells, and distributes medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Its products are developed from the AROA extracellular matrix (ECM) technology platform, an extracellular matrix biomaterial derived from ovine forestomach. AROA ECM is an ECM biomaterial containing a rich and complex mix of biological molecules that is the building block for a range of soft tissue repair products. Its products include Endoform, Myriad Matrix, Myriad Morcells, Myriad Morcells Fine, and Reinforced Bioscaffolds. Endoform products support all phases of wound healing and are appropriate for use early in wound management to restore protease balance and advance healing to the proliferative phase. Myriad Matrix is an engineered ECM for soft tissue repair, reinforcement and complex wounds. Its subsidiaries are Aroa Biosurgery Incorporated and Mesynthes Nominee Limited.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.5653 NZD
Average target price
1.108 NZD
Spread / Average Target
+95.97%
Consensus

Quarterly revenue - Rate of surprise

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW